ID
29542
Description
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Pneumonia Assessment
Keywords
Versions (2)
- 3/21/18 3/21/18 -
- 4/5/18 4/5/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
April 5, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463
Similar models
Pneumonia Assessment
- StudyEvent: ODM
C0024117 (UMLS CUI-2)
C0220825 (UMLS CUI-3)
C0031809 (UMLS CUI-4)
C0574845 (UMLS CUI [1,2])
C0200949 (UMLS CUI [1,2])
C0032285 (UMLS CUI [1,3])
C1515974 (UMLS CUI [1,2])
C0086388 (UMLS CUI [1,2])
C0205721 (UMLS CUI [2])
C0032285 (UMLS CUI [1,2])
C0032285 (UMLS CUI [1,2])
No comments